Risk-benefit analysis for drotrecogin alfa (activated)

Roland Schein, Gary T. Kinasewitz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

An analysis of risks and benefits is an important component of patient care. Drotrecogin alfa (activated), the first approved cogin (a class of recombinant human coagulation inhibitors), provides a clear example of a treatment that requires a careful risk-benefit analysis. Treatment with this novel compound has been shown to reduce significantly the risk of death in patients with sepsis and acute organ dysfunction (severe sepsis). However, the drug is a natural antithrombotic that can increase the risk of bleeding in recipients. We will discuss bleeding and other potential risks associated with drotrecogin alfa (activated) treatment, as well as the survival benefits seen with the use of this therapy in patients with severe sepsis.

Original languageEnglish
JournalAmerican Journal of Surgery
Volume184
Issue number6 SUPPL. 1
StatePublished - Dec 1 2002

Fingerprint

Sepsis
Hemorrhage
Therapeutics
Patient Care
Survival
drotrecogin alfa activated
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery

Cite this

Risk-benefit analysis for drotrecogin alfa (activated). / Schein, Roland; Kinasewitz, Gary T.

In: American Journal of Surgery, Vol. 184, No. 6 SUPPL. 1, 01.12.2002.

Research output: Contribution to journalArticle

Schein, Roland ; Kinasewitz, Gary T. / Risk-benefit analysis for drotrecogin alfa (activated). In: American Journal of Surgery. 2002 ; Vol. 184, No. 6 SUPPL. 1.
@article{e772b3e375654c8fabac5be918cffba1,
title = "Risk-benefit analysis for drotrecogin alfa (activated)",
abstract = "An analysis of risks and benefits is an important component of patient care. Drotrecogin alfa (activated), the first approved cogin (a class of recombinant human coagulation inhibitors), provides a clear example of a treatment that requires a careful risk-benefit analysis. Treatment with this novel compound has been shown to reduce significantly the risk of death in patients with sepsis and acute organ dysfunction (severe sepsis). However, the drug is a natural antithrombotic that can increase the risk of bleeding in recipients. We will discuss bleeding and other potential risks associated with drotrecogin alfa (activated) treatment, as well as the survival benefits seen with the use of this therapy in patients with severe sepsis.",
author = "Roland Schein and Kinasewitz, {Gary T.}",
year = "2002",
month = "12",
day = "1",
language = "English",
volume = "184",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "6 SUPPL. 1",

}

TY - JOUR

T1 - Risk-benefit analysis for drotrecogin alfa (activated)

AU - Schein, Roland

AU - Kinasewitz, Gary T.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - An analysis of risks and benefits is an important component of patient care. Drotrecogin alfa (activated), the first approved cogin (a class of recombinant human coagulation inhibitors), provides a clear example of a treatment that requires a careful risk-benefit analysis. Treatment with this novel compound has been shown to reduce significantly the risk of death in patients with sepsis and acute organ dysfunction (severe sepsis). However, the drug is a natural antithrombotic that can increase the risk of bleeding in recipients. We will discuss bleeding and other potential risks associated with drotrecogin alfa (activated) treatment, as well as the survival benefits seen with the use of this therapy in patients with severe sepsis.

AB - An analysis of risks and benefits is an important component of patient care. Drotrecogin alfa (activated), the first approved cogin (a class of recombinant human coagulation inhibitors), provides a clear example of a treatment that requires a careful risk-benefit analysis. Treatment with this novel compound has been shown to reduce significantly the risk of death in patients with sepsis and acute organ dysfunction (severe sepsis). However, the drug is a natural antithrombotic that can increase the risk of bleeding in recipients. We will discuss bleeding and other potential risks associated with drotrecogin alfa (activated) treatment, as well as the survival benefits seen with the use of this therapy in patients with severe sepsis.

UR - http://www.scopus.com/inward/record.url?scp=0036939294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036939294&partnerID=8YFLogxK

M3 - Article

C2 - 12521615

AN - SCOPUS:0036939294

VL - 184

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 6 SUPPL. 1

ER -